Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannTrust CBD Drops
- Development stage
- Unknown
- Lead developer
- CannTrust
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**CannTrust CBD Drops** is an oral cannabis oil formulation developed and manufactured by CannTrust for the Canadian medical-cannabis market. Each 40 mL bottle contains 1,000 mg cannabidiol and 80 mg tetrahydrocannabinol in medium-chain triglyceride oil, corresponding to 25 mg/mL cannabidiol and 2 mg/mL tetrahydrocannabinol. Tetrahydrocannabinol is a partial agonist of cannabinoid receptors 1 and 2, while cannabidiol has complex, comparatively low-affinity cannabinoid-receptor activity and may modulate endocannabinoid signaling. The product was supplied with a 1 mL oral dosing syringe.
- Brand names
- CannTrust CBD Drops
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on CannTrust CBD Drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CannTrust CBD Drops.